In his latest op-ed for BioSpace, Craig Koch examines why this moment matters for European clinical research. Read Craig’s full analysis here: biospace.com/drug-developme… #ClinicalResearch #Europe #Biopharma #GlobalTrials #PolicyReform

We’re proud to be a founding member of Advarra’s newly launched Council for Responsible Use of AI in Clinical Trials alongside Sanofi and Recursion. Read the full announcement: advarra.com/news/advarra-e… #ClinicalResearch #AI #ClinicalTrials #Innovation #LifeSciences

We're committed to addressing disparities in healthcare access and outcomes. We strive to conduct research that represents diverse populations, including Black individuals, to ensure that everyone has equal opportunities for optimal health. Learn more: velocityclinical.com/diversity.

Tremendous results! Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly's Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss. investor.lilly.com/news-releases/…

Julio Rosenstock, MD, has two original articles featured in this week's New England Journal of Medicine email newsletter, with an article featured on the NEJM.org homepage. Orforglipron: nejm.org/doi/full/10.10… Efsitora: nejm.org/doi/full/10.10…

Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” nature.com/articles/s4146…

Velocity taps into the expertise of our leading Principal Investigators and CARE Council members to review protocols. Internally, their feedback helps assess trials, align resources effectively. Externally, PI feedback has influenced study design. velocityclinical.com/capabilities/

Velocity’s Cardiometabolic Council to Accelerate Research Excellence (CARE) provides high-impact strategies for operational efficiency, recruitment, and trial execution at Velocity sites specializing in cardiology, metabolic, and related research. velocityclinical.com/cardiometaboli…

Today we announced our strategic partnership with Palantir Technologies, bringing cutting-edge AI to one of the clinical trial industry’s most frustrating pain points: payment reconciliation. Read more: shorturl.at/i1qAX #ClinicalTrials #AI #HealthcareInnovation

William Cromwell, MD, FAHA, FNLA, shares his perspective on how targeted treatments are reshaping cardiometabolic research, and why now is an ideal moment to leverage expertise at scale. Learn more about Velocity's Cardiometabolic CARE Council: velocityclinical.com/cardiometaboli…